MedyMatch Technology and IBM Watson Health have partnered to integrate MedyMatch's artificial intelligence (AI) based clinical decision support application into cognitive imaging offerings.

The move aims to assist imaging experts in hospital emergency rooms and other acute care settings, to identify instances of intracranial bleeding due to head trauma and stroke.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

IBM Watson Health's Imaging group will initially distribute the MedyMatch brain bleed detection application through its vendor neutral sales channels.

The firms will then develop interoperability between MedyMatch's application and IBM Watson Health Imaging's offerings.

MedyMatch chairman and chief executive officer Gene Saragnese said: "Engaging closely with IBM allows for a near-zero footprint implementation at a customer location delivering AI to the bedside where I believe the future of healthcare lies.

"At MedyMatch, we believe improvements in the interpretation of data will lead to better decisions, better decisions will lead to better outcomes for patients and lower cost for healthcare."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"The MedyMatch algorithm utilises deep learning, machine vision, patient data, and clinical insights to automatically highlight the regions of interest that could indicate the potential presence of cerebral bleeds."

The firm primarily focuses on providing cognitive tools to the emergency department for helping physicians in the assessment of presence of bleed in the brain of patients suspected of head trauma or stroke.

The MedyMatch algorithm utilises deep learning, machine vision, patient data, and clinical insights to automatically highlight the regions of interest that could indicate the potential presence of cerebral bleeds.

MedyMatch's intracranial bleed assessment application is currently undergoing a clinical trial, based on which the firm intends to apply for a pre-marketing approval (PMA) to the US Food and Drug Administration (FDA).

Image: MedyMatch's intracranial bleed detection application and 3D rendering of bleed location and volume. Photo: courtesy of  IBM Watson Health.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact